# Balchem Corporation (BCPC) — Financial Analysis

**Exchange:** NASDAQ  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-29  
**Tier:** Free primer (step 2 of 19)  
**Sibling pages:** /stocks/BCPC/thesis · /stocks/BCPC/memo

## Financial Snapshot

---
source: coverage-next-full
ticker: BCPC
step: "04"
title: Financial Snapshot
created: 2026-05-29
---

### Step 04: Financial Snapshot — Balchem Corporation (BCPC)

#### Three-Year P&L Summary

| Metric | FY2021 | FY2022 | FY2023 |
|--------|--------|--------|--------|
| Revenue | $751.8M | $952.1M | ~$926M |
| Revenue Growth YoY | +24.3% | +26.6% | -2.7% |
| Gross Profit | ~$270M | ~$320M | ~$305M |
| Gross Margin | ~35.9% | ~33.6% | ~33.0% |
| Operating Income (GAAP) | ~$120M | ~$150M | ~$140M |
| GAAP Operating Margin | ~16.0% | ~15.8% | ~15.1% |
| Adjusted EBITDA | ~$180M | ~$225M | ~$215M |
| Adjusted EBITDA Margin | ~23.9% | ~23.6% | ~23.2% |
| Net Income (GAAP) | ~$90M | ~$108M | ~$100M |
| Diluted EPS (GAAP) | ~$2.74 | ~$3.30 | ~$3.06 |
| Adjusted EPS | ~$3.50 | ~$4.35 | ~$4.10 |

Note: FY2022 jump reflects full-year Kappa Bioscience contribution (acquired November 2021) plus organic HNH growth and pricing. FY2023 revenue moderation reflects ANH softness and EtO regulatory environment.

#### Revenue Bridge: 2021 to 2023

- **Kappa Bioscience:** Added ~$30M annual run-rate revenue to HNH; partially explains the large 2022 step-up alongside organic growth
- **Pricing:** Meaningful contribution in 2022 as Balchem passed through raw material cost increases; partially reversed in 2023 as input costs moderated
- **Volume:** Core HNH volume grew mid-single digits organically; ANH volumes moderated in 2023

#### Margin Analysis

##### Gross Margin

Gross margin has trended at 33–36% over the past three years. The compression from 2021 to 2022-2023 reflects:
- Input cost inflation (choline chloride, energy, packaging) in 2022 that was not fully passed through immediately
- Kappa Bioscience gross margins initially dilutive to total company margins as integration and Norway-to-US shipping economics were optimized
- Industrial segment volume at lower margins diluting total company

Premium segments (HNH, Specialty Products) generate gross margins in the 40–50% range; ANH is approximately 35%; Industrial is the drag at 15–20%.

##### EBITDA and Operating Margin

Balchem's adjusted EBITDA margin has historically been in the 22–26% range, reflecting:
- High R&D intensity relative to commodity peers (~2% of revenue in food science, nutrition research)
- Sales force investment (nutritional consultants for ANH, technical sales for HNH)
- Regulatory and quality compliance infrastructure

GAAP operating margin is lower (~15%) due to amortization of acquired intangibles (significant from Kappa acquisition, with identifiable intangibles of ~$80–100M amortizing over useful lives).

##### D&A and Non-Cash Items

- **Depreciation:** ~$30–35M annually (moderate capital intensity)
- **Amortization:** ~$30–40M annually (acquisition-related; elevated post-Kappa)
- **Stock-based compensation:** ~$15–20M annually
- **Non-cash pension:** Minimal

Adjusted EPS (management's non-GAAP figure) adds back amortization and other one-time items. The gap between GAAP and adjusted EPS (~$1.00–$1.25) is primarily amortization of acquisition intangibles.

#### Profitability by Segment (FY2023 Approximate)

| Segment | Revenue | Operating Income | Op. Margin |
|---------|---------|-----------------|-----------|
| Human Nutrition & Health | ~$470M | ~$85M | ~18% |
| Animal Nutrition & Health | ~$230M | ~$50M | ~22% |
| Specialty Products | ~$140M | ~$45M | ~32% |
| Industrial | ~$90M | ~$8M | ~9% |
| Corporate/Unallocated | — | -$45M | — |
| **Total** | **~$930M** | **~$143M** | **~15%** |

Note: Specialty Products carries the highest segment operating margin (~30–35%) due to regulated market dynamics, low customer acquisition costs, and low manufacturing complexity relative to HNH.

#### Kappa Bioscience Acquisition Impact

**Transaction:** Acquired November 2021 for approximately NOK 2.15 billion (~$237M USD at time of close)

**Rationale:** 
- Vitamin K2 (menaquinone MK-7) market growing 10%+ annually
- Kappa's K2VITAL and MenaquinGold brands were the premium-quality reference in the supplement and pharmaceutical ingredient markets
- Geographic diversification (European manufacturing, global customer relationships)
- Margin accretive once integrated (high gross margins on branded specialty ingredients)

**Financial Impact:**
- Added estimated $25–35M in annual revenue (2022 full-year)
- Added ~$80–100M in identifiable intangibles (customer relationships, technology, brand) + goodwill
- Incremental debt (~$200M drawn from revolving credit facility) increased leverage to ~2x net debt/EBITDA at close
- Leverage has been reduced since through strong free cash flow generation

#### Free Cash Flow

| Year | FCF ($M) | FCF Conversion (% Net Income) |
|------|----------|-------------------------------|
| FY2021 | ~$120M | ~133% |
| FY2022 | ~$145M | ~134% |
| FY2023 | ~$130M | ~130% |

Free cash flow conversion is consistently above 100% of net income, reflecting:
- Non-cash charges (D&A, SBC) that are real costs but don't consume cash in the year
- Working capital discipline
- Modest CapEx requirements (~$35–45M annually) — no major greenfield facilities required; existing network largely adequate

#### Dividend Track Record

Balchem has increased its dividend for 30+ consecutive years — qualifying as a **Dividend Champion** (often confused with Dividend Aristocrats, which requires S&P 500 membership):

| Year | Annual Dividend | YoY Growth |
|------|----------------|-----------|
| 2020 | $0.56 | +17% |
| 2021 | $0.64 | +14% |
| 2022 | $0.72 | +13% |
| 2023 | $0.80 | +11% |
| 2024 | ~$0.88 | ~+10% |

Payout ratio is modest (~25–30% of GAAP net income, ~18–22% of FCF) — ample coverage and room for continued growth.

#### Valuation Context

At recent market prices of ~$110–130/share, BCPC trades at:
- **P/E (GAAP):** ~35–42x trailing
- **P/E (Adjusted):** ~27–33x
- **EV/EBITDA:** ~18–22x adjusted EBITDA
- **EV/Revenue:** ~4–5x

Premium multiples reflect: consistent compounding, moat characteristics, dividend growth record, and scarcity of comparable public companies (there is no perfect comp). The premium is partially a function of BCPC's small float and limited institutional penetration.

## Deeper Financial Analysis

The fundamental tier ($1.00) adds 8 dimensions not included here:

- Revenue Breakdown — segment revenue, geographic mix, product-line margins
- Financial Trends — QoQ momentum, leading indicators, inflection points
- Balance Sheet — debt structure, dilution risk, working capital dynamics
- Capital Allocation — ROIC, buyback cadence, reinvestment efficiency
- Earnings Analysis — beats/misses, guidance vs actuals, transcript highlights
- Competitive Positioning — market share, pricing power, peer benchmarks
- Industry Context — TAM, sector tailwinds/headwinds, regulatory backdrop

**API endpoint:** GET /api/v1/research/BCPC/fundamental

## Navigation

- Overview: /stocks/BCPC
- Financials (this page): /stocks/BCPC/financials
- Thesis: /stocks/BCPC/thesis
- Investment Memo: /stocks/BCPC/memo
- Coverage universe: /stocks